Management
Dr. Simon J. Ittig
Chief Executive Officer
Simon completed a PhD on microbial pathogenesis at the University of Basel in the framework of the Werner Siemens Excellence fellowships. He started working on the T3 Pharma technology during his postdoctoral studies at the Biozentrum. For these achievements he received the Novartis and University of Basel Excellence Scholarship in 2014 and a research prize from the Huggenberger-Bischoff foundation for cancer research in the same year.
Dr. Christoph A. Kasper
Chief Scientific Officer
Christoph holds a PhD in cell biology from the University of Basel, which he performed in the framework of the Werner Siemens Excellence fellowships. He acquired profound knowledge in host-microbe interactions and inflammation signaling. Christoph has hands-on experience in high-throughput screening and is skilled in automated image analysis.
Prof. Dr. med. Gerd Munzert
Chief Medical Officer
Gerd is a hematologist/medical oncologist with over 20 years of experience in anticancer drug development. After attending medical school in Freiburg and Munich he did postdoctoral research at the University of Michigan working on G-protein receptors in the lab of Prof. T. Yamada. In his further academic career he focused on pathophysiology and treatment of leukemias and lymphomas at Ulm University where he maintains an affiliation as a lecturer. After joining Boehringer Ingelheim Pharma he worked in different roles in the therapeutic area of oncology. He successfully led and steered clinical development of NCEs such as antimitotic kinases, EGFR tyrosine kinases and other targeted agents. After serving as Chief Medical Officer for NBE Therapeutics from 2021 to 2024 he joined T3 Pharmaceuticals as CMO in April 2024.